Former Big Pharma Executives See Gold in Consolidation's Cast-Offs
Executive SummaryTop executives from Big Pharmas, like Jan Leschley of SmithKline and Tony Wild of Warner-Lambert, are now taking a run at venture capital--figuring that their rolodexes and understanding of drug-company requirements will give them a big advantage in starting new companies. The question is whether these contacts will be of much help during periods when financing is difficult--that's when real VC experience comes in handy.
You may also be interested in...
CMR Surgical’s Versius robotic system is now live in the UK NHS, the company announced 20 February.